Holocene Advisors’s BioMarin Pharmaceuticals BMRN Stock Holding History

Holocene Advisors’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$660K	Hold	11,679	–	–	﹤0.01%	710
2025 Q4	$694K	Buy	11,679 +6,281	+116%	+$342K	﹤0.01%	642
2025 Q3	$292K	Sell	5,398 -3,072	-36%	-$176K	﹤0.01%	714
2025 Q2	$466K	Hold	8,470	–	–	﹤0.01%	705
2025 Q1	$599K	Buy	+8,470	New	+$570K	﹤0.01%	662
2024 Q4	–	Sell	-563,476	Closed	-$39.6M	–	763
2024 Q3	$39.6M	Sell	563,476 -149,628	-21%	-$12.5M	0.16%	172
2024 Q2	$58.7M	Buy	713,104 +517,108	+264%	+$43M	0.25%	125
2024 Q1	$17.1M	Buy	+195,996	New	+$17.5M	0.06%	224
2018 Q2	–	Sell	-3,139	Closed	-$254K	–	584
2018 Q1	$254K	Sell	3,139 -8,074	-72%	-$693K	0.01%	433
2017 Q4	$1M	Buy	+11,213	New	+$975K	0.03%	129

Other funds holding BMRN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Holocene Advisors's BMRN Position: Q1 2026 in Review

Holocene Advisors held its BioMarin Pharmaceuticals (BMRN) position steady in Q1 2026 at 11,679 shares worth $660K. The position accounts for ﹤0.01% of the portfolio, ranked #710.

Holocene Advisors first reported a position in BMRN in Q4 2017 and has held it in 10 quarters since. The position peaked at $58.7M in Q2 2024. 554 funds tracked by Wall St. Rank hold BMRN as of Q1 2026.

Holocene Advisors held 11,679 shares of BioMarin Pharmaceuticals worth $660K as of Q1 2026.
Holocene Advisors left its BioMarin Pharmaceuticals share count unchanged in Q1 2026.
BioMarin Pharmaceuticals made up ﹤0.01% of Holocene Advisors's portfolio in Q1 2026, its #710 holding.
Holocene Advisors first reported a position in BioMarin Pharmaceuticals in Q4 2017 and has held it in 10 quarters since.
Holocene Advisors's BioMarin Pharmaceuticals position peaked at $58.7M in Q2 2024.
554 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2026.

Based on Holocene Advisors's 13F filing for Q1 2026, filed 15 May 2026.